Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

被引：9

作者：

Suzuki, Keito ^{[1
]}

Yasui, Yutaka ^{[1
]}

Tsuchiya, Kaoru ^{[1
]}

Matsumoto, Hiroaki ^{[1
]}

Yamazaki, Yudai ^{[1
]}

Uchihara, Naoki ^{[1
]}

Tanaka, Yuki ^{[1
]}

Miyamoto, Haruka ^{[1
]}

Yamada-Shimizu, Michiko ^{[1
]}

Keitoku, Taisei ^{[1
]}

Okada, Risa ^{[1
]}

Higuchi, Mayu ^{[1
]}

Takaura, Kenta ^{[1
]}

Tanaka, Shohei ^{[1
]}

Maeyashiki, Chiaki ^{[1
]}

Tamaki, Nobuharu ^{[1
]}

Nakanishi, Hiroyuki ^{[1
]}

Takahashi, Yuka ^{[1
]}

Asahina, Yasuhiro ^{[2
]}

Okamoto, Ryuichi ^{[2
]}

Kurosaki, Masayuki ^{[1
,3
]}

Izumi, Namiki ^{[1
]}

机构：

[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[2] Tokyo Med Dent Univ, Dept Gastroenterol & Hepatol, Tokyo, Japan

[3] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Kyonan Cho 1-26-1, Musashino, Tokyo 1808610, Japan

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷 / 06期

关键词：

atezolizumab; bevacizumab; hepatocellular carcinoma; immune-related adverse events; SORAFENIB;

D O I：

10.1111/jgh.16532

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aim: Immune checkpoint inhibitors pose the risk of immune-related adverse events (irAEs). Recent data suggest that irAEs may be associated with a favorable prognosis. This study aimed to investigate and analyze the association between these adverse events and the clinical benefits in patients with unresectable hepatocellular carcinoma. Methods: The study enrolled 130 patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab between November 2020 and January 2023 at a single center. The relationship between irAEs and both response rate and post-treatment outcomes was investigated. Results: Out of the 130 patients, irAEs developed in 36 (27.7%) patients. The irAE group exhibited a significantly longer progression-free survival (PFS) than the non-irAE group, with a median PFS of 8.9 compared with 4.6 months (P < 0.01). No difference was found in the overall survival between the irAE and non-irAE groups. The irAE group demonstrated significantly higher disease control rate (DCR) than the non-irAE group (97.0% vs 65.5%, P < 0.01). The analysis by irAE severity revealed that the grade 1/2 group exhibited significantly longer PFS (7.9 vs 4.6 months, P = 0.007) and higher DCR (100% vs 65.5%, P < 0.01) than the non-irAE group. Furthermore, hypothyroidism correlated with a favorable PFS (8.9 vs 5.4 months, P = 0.02), DCR (100% vs 71.3%, P = 0.03), and overall response rate (58.3% vs 18.5%, P = 0.005). Conclusion: The presence of irAEs is associated with prolonged PFS and higher DCR. Specifically, mild irAEs (grade 1/2) and hypothyroidism displayed prolonged PFS and higher DCR.

引用

页码：1183 / 1189

页数：7

共 30 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2]

Abou-Alfa GK, 2022, NEJM EVID, V1, DOI 10.1056/EVIDoa2100070

[3]

Abu-Sbeih, 2018, J IMMUNOTHER PRECIS, V1, P7, DOI [10.4103/JIPO.JIPO_12_18, DOI 10.4103/JIPO.JIPO_12_18]

[4] The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [J].

Akinyemiju, Tomi ;

Abera, Semaw ;

Ahmed, Muktar ;

Alam, Noore ;

Alemayohu, Mulubirhan Assefa ;

Allen, Christine ;

Al-Raddadi, Rajaa ;

Alvis-Guzman, Nelson ;

Amoako, Yaw ;

Artaman, Al ;

Ayele, Tadesse Awoke ;

Barac, Aleksandra ;

Bensenor, Isabela ;

Berhane, Adugnaw ;

Bhutta, Zulfiqar ;

Castillo-Rivas, Jacqueline ;

Chitheer, Abdulaal ;

Choi, Jee-Young ;

Cowie, Benjamin ;

Dandona, Lalit ;

Dandona, Rakhi ;

Dey, Subhojit ;

Dicker, Daniel ;

Phuc, Huyen ;

Ekwueme, Donatus U. ;

Zaki, Maysaa El Sayed ;

Fischer, Florian ;

Furst, Thomas ;

Hancock, Jamie ;

Hay, Simon I. ;

Hotez, Peter ;

Jee, Sun Ha ;

Kasaeian, Amir ;

Khader, Yousef ;

Khang, Young-Ho ;

Kumar, G. Anil ;

Kutz, Michael ;

Larson, Heidi ;

Lopez, Alan ;

Lunevicius, Raimundas ;

Malekzadeh, Reza ;

McAlinden, Colm ;

Meier, Toni ;

Mendoza, Walter ;

Mokdad, Ali ;

Moradi-Lakeh, Maziar ;

Nagel, Gabriele ;

Nguyen, Quyen ;

Nguyen, Grant ;

Ogbo, Felix .

JAMA ONCOLOGY, 2017, 3 (12) :1683-1691

[5] Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy [J].

Bai, Xue ;

Hu, Jiani ;

Warner, Allison Betof ;

Quach, Henry T. ;

Cann, Christopher G. ;

Zhang, Michael Z. ;

Si, Lu ;

Tang, Bixia ;

Cui, Chuanliang ;

Yang, Xiaoling ;

Wei, Xiaoting ;

Pallan, Lalit ;

Harvey, Catriona ;

Manos, Michael P. ;

Ouyang, Olivia ;

Kim, Michelle S. ;

Kasumova, Gyulnara ;

Cohen, Justine V. ;

Lawrence, Donald P. ;

Freedman, Christine ;

Fadden, Riley M. ;

Rubin, Krista M. ;

Sharova, Tatyana ;

Frederick, Dennie T. ;

Flaherty, Keith T. ;

Rahma, Osama E. ;

Long, Georgina V. ;

Menzies, Alexander M. ;

Guo, Jun ;

Shoushtari, Alexander N. ;

Johnson, Douglas B. ;

Sullivan, Ryan J. ;

Boland, Genevieve M. .

CLINICAL CANCER RESEARCH, 2021, 27 (21) :5993-6000

[6] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[7]

Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]

[8] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[9] Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab [J].

Fukushima, Taito ;

Morimoto, Manabu ;

Kobayashi, Satoshi ;

Ueno, Makoto ;

Uojima, Haruki ;

Hidaka, Hisashi ;

Kusano, Chika ;

Chuma, Makoto ;

Numata, Kazushi ;

Tsuruya, Kota ;

Arase, Yoshitaka ;

Kagawa, Tatehiro ;

Hattori, Nobuhiro ;

Ikeda, Hiroki ;

Watanabe, Tsunamasa ;

Tanaka, Katsuaki ;

Maeda, Shin .

ONCOLOGIST, 2023, 28 (07) :E526-E533

[10] Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis [J].

Hiraoka, Atsushi ;

Kumada, Takashi ;

Tsuji, Kunihiko ;

Takaguchi, Koichi ;

Itobayashi, Ei ;

Kariyama, Kazuya ;

Ochi, Hironori ;

Tajiri, Kazuto ;

Hirooka, Masashi ;

Shimada, Noritomo ;

Ishikawa, Toru ;

Tachi, Yoshihiko ;

Tada, Toshifumi ;

Toyoda, Hidenori ;

Nouso, Kazuhiro ;

Joko, Kouji ;

Hiasa, Yoichi ;

Michitaka, Kojiro ;

Kudo, Masatoshi .

LIVER CANCER, 2019, 8 (02) :121-129

← 1 2 3 →